Mr. Hugh Rogers reports

BIONXT SOLUTIONS REPORTS EXPANDED PATENT PROTECTION FROM THE EURASIAN PATENT ORGANIZATION

Bionxt Solutions Inc.'s first national-level patent filing has been accepted by the Eurasian Patent Organization (EAPO). The EAPO has confirmed the company's core patent claims, namely novelty, inventive step and industrial applicability.

Bionxt's flagship patent filing, which received a positive international examination report from the European Patent Office, reported Sept. 9, 2024, is a comprehensive patent application for sublingual delivery of anti-cancer drugs for the treatment of autoimmune neurodegenerative diseases. This patent family provides numerous proprietary product development and commercialization opportunities, including Bionxt's lead product, BNT23001, a sublingual thin-film formulation of cladribine for the treatment of multiple sclerosis (MS).

The EAPO covers Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan and Turkmenistan. These countries are the members of the Eurasian Patent Convention (EAPC), which provides a single, harmonized patent application process and regulator for the region. The EAPO grants Eurasian patents that are valid in all eight member states.

Bionxt continues to advance the nationalization phase of the patent protection process at the European Patent Office and Eurasian Patent Organization, as well as with independent filing nations such as Australia, Canada, New Zealand, the United States and Japan. Securing national-level patents around the globe will serve as the foundation for commercial opportunities for the company's pipeline of sublingual products targeting autoimmune diseases such as multiple sclerosis (MS), myasthenia gravis (MG), lupus nephritis (LN) and rheumatoid arthritis (RA).

About Bionxt Solutions Inc.

Bionxt Solutions is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems and active pharmaceutical ingredient development. The company's proprietary platforms -- sublingual (thin film), transdermal (skin patch) and oral (enteric-coated tablets) -- target key therapeutic areas, including autoimmune diseases, neurological disorders and longevity.

With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

Bionxt is listed on the Canadian Securities Exchange under the symbol BNXT and on the OTC Markets under the symbol BNXTF and trades in Germany under WKN: A3D1K3.

We seek Safe Harbor.